Results 101 to 110 of about 10,444 (254)

CONSULTAS SOBRE USO DE CANNABIS MEDICINAL RECIBIDAS POR EQUIPOS DE CUIDADOS PALIATIVOS EN 9 CIUDADES DE LA ARGENTINA: UNA ENCUESTA MULTISITIO

Revistas Argentina de Medicina, 2017
Introducción. El uso de cannabis medicinal es una práctica popular en Argentina entre los pacientes que reciben cuidados paliativos, aun cuando no reciben prescripción médica para tal fin. Materiales y métodos.
Ariel Fabián Cherro, Cecilia Lorena Lupi, Ronaldo Pedraza Vargas   +2 more
doaj   +2 more sources

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

Addiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne, Will Lawn, Kat Petrilli, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H. Valerie Curran, Lindsey A. Hines, Tom P. Freeman   +9 more
wiley   +1 more source

From farm to bedside: Potential of medical cannabis in global health

Complementary Therapies in Medicine
Introduction: The growing opioid crisis and persistent global health disparities underscore the urgent need for alternative therapeutic strategies.
Maureen Bilinga Tendwa, Tejaswini Appidi, Brylyne Chitsunge, Michele Moreau, Blessed Okole, Lonji Kalombo, Abba Mallum, Twalib Ngoma, Daniel P. Weadock, Eric Tanifum, Simon Erridge, Mikael Sodergren, Rob Sims, Calvin Johnson, Ngeh Toyang, Henry Lowe, Bashkim Ziberi, Luc Richner, Sandra Carrillo, Stephen Avery, Judey Pretorius, Rachel Chikwamba, Fleury A.Nsole Biteghe, Peter Grinspoon, Gary Strichtartz, Sayeda Yasmin-Karim, Wilfred Ngwa   +26 more
doaj   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Cannabis as a medicine

British Journal of Anaesthesia, 1995
E, Doyle, A A, Spence
openaire   +3 more sources

SYSTEMATIC REVIEW OF MEDICINAL BENEFITS OF CANNABIS SATIVA L. AND ITS IMPACT ON SOCIO-ECONOMIC DEVELOPMENT.

Student's Journal of Health Research Africa
Medical Cannabis sativa inflorescence has gained popularity in recent years due to the therapeutic pharmacological characteristics of its components. Cannabis sativa L.-based drugs are effective in treating a variety of illnesses, including constipation,
Sipho Goge, Karishma Singh, Kuben Naidoo   +2 more
doaj   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer, Tom P. Freeman, Martine Skumlien, Esther Walton, Thomas Lancaster, Jorien L. Treur, Valentina Lorenzetti, Anna K. M. Blackwell, Chloe Burke, Richie J. Carr, Constantinos Constantinides, Maisie Cox, Sarah Dance, Shadi Daryan, Sorcha Hamilton, Tom Jenkins, Gemma M. J. Taylor   +16 more
wiley   +1 more source

Proportions and correlates of high‐risk cannabis use in Australia—A cross‐sectional analysis of the 2022–2023 National Drug Strategy Household Survey

Addiction, EarlyView.
Abstract Background and aim Cannabis use is prevalent in Australia, however, limited research has explored the levels of high‐risk cannabis use within nationally representative samples. This study aimed to address this gap by examining the proportion of individuals meeting criteria for high‐risk cannabis use and identifying its correlates in a ...
Janni Leung, Daniel Stjepanović, Gary Chung Kai Chan, Wayne Denis Hall, Danielle Dawson   +4 more
wiley   +1 more source